Pan-ELR+ CXC chemokine antibodies
AssigneeEli Lilly and Company
InventorsCatherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher, Sudhakar Reddy Chintharlapalli
Life of this patent
Estimating the term…
Abstract
Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
Claims10
A method of treating one of renal cancer or ovarian cancer in a patient, comprising administering to the patient a therapeutically effective amount of an antibody that binds human growth-regulated oncogene (“Gro”)-alpha, human Gro-beta, human Gro-gamma, human epithelial neutrophil activating peptide-78, human granulocyte chemotactic protein-2, human neutrophil activating protein-2, and human interleukin-8, the antibody comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises light chain complementarity determining regions (“LCDR”) LCDR1, LCDR2, LCDR3 and the HCVR comprises heavy chain complementarity determining regions (“HCDR”) HCDR1, HCDR2, HCDR3, wherein LCDR1 is RASQSISNNLH (SEQ ID NO:
- 7), LCDR2 is YTSRSVS (SEQ ID NO:
- 8), LCDR3 is GQNNEWPEV (SEQ ID NO:
- 9), HCDR1 is GYEFTSYWIH (SEQ ID NO:
- 10), HCDR2 is NISPNSGSANYNEKFKS (SEQ ID NO:
- 11), and HCDR3 is EGPYSYYPSRXaaYYGSDL (SEQ ID NO:
- 20) wherein Xaa is E or Q.
A method of treating one of renal cancer or ovarian cancer in a patient, comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition, said pharmaceutical composition comprising an antibody and one or more pharmaceutically acceptable carriers, diluents or excipients, the antibody comprising a light chain and a heavy chain, wherein the light chain comprises a light chain variable region (LCVR) and the heavy chain comprises a heavy chain variable region (HCVR), wherein the LCVR comprises light chain complementarity determining regions (“LCDR”) LCDR1, LCDR2, LCDR3 and the HCVR comprises heavy chain complementarity determining regions (“HCDR”) HCDR1, HCDR2, HCDR3, wherein LCDR1 is RASQSISNNLH (SEQ ID NO:
- 7), LCDR2 is YTSRSVS (SEQ ID NO:
- 8), LCDR3 is GQNNEWPEV (SEQ ID NO:
- 9), HCDR1 is GYEFTSYWIH (SEQ ID NO:
- 10), HCDR2 is NISPNSGSANYNEKFKS (SEQ ID NO:
- 11), and HCDR3 is EGPYSYYPSRXaaYYGSDL (SEQ ID NO:
- 20) wherein Xaa is E or Q.
Dependencies are inferred from the claim text.